| scholarly article | Q13442814 |
| P50 | author | James A. Duce | Q39061729 |
| Bruce X. Wong | Q39061741 | ||
| P2860 | cites work | A synthetic peptide with the putative iron binding motif of amyloid precursor protein (APP) does not catalytically oxidize iron | Q21134149 |
| The amyloid precursor protein (APP) does not have a ferroxidase site in its E2 domain | Q21559570 | ||
| Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes | Q22337213 | ||
| Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease | Q24298553 | ||
| Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease | Q24305330 | ||
| Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice | Q24568007 | ||
| Regulation of cellular iron metabolism | Q24610063 | ||
| Generating a prion with bacterially expressed recombinant prion protein | Q24626352 | ||
| Prions | Q24633319 | ||
| Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease | Q24656549 | ||
| Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases | Q26827257 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases | Q40495053 | ||
| Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells | Q40613073 | ||
| Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 | ||
| Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease | Q41117111 | ||
| Selective neuronal requirement for huntingtin in the developing zebrafish | Q42131524 | ||
| Alteration of iron regulatory proteins (IRP1 and IRP2) and ferritin in the brains of scrapie-infected mice | Q42181538 | ||
| Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains | Q42477389 | ||
| Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain | Q42504905 | ||
| Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease | Q42506652 | ||
| In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice | Q42556926 | ||
| Aβ interacts with both the iron center and the porphyrin ring of heme: mechanism of heme's action on Aβ aggregation and disaggregation | Q42713522 | ||
| Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. | Q42916945 | ||
| Iron and reactive oxygen species activity in parkinsonian substantia nigra | Q43135073 | ||
| Differential effect of nimodipine in attenuating iron-induced toxicity in brain- and blood-brain barrier-associated cell types | Q43578005 | ||
| An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript | Q44116151 | ||
| Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. | Q44163214 | ||
| Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 | ||
| Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system | Q44438522 | ||
| Redox metals and oxidative abnormalities in human prion diseases | Q44823992 | ||
| Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. | Q45234671 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. | Q45305391 | ||
| Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. | Q45845994 | ||
| Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. | Q46009075 | ||
| α-Synuclein expression is modulated at the translational level by iron | Q46496494 | ||
| Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease | Q46531893 | ||
| Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway | Q46537593 | ||
| Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease | Q47767512 | ||
| Heme prevents amyloid beta peptide aggregation through hydrophobic interaction based on molecular dynamics simulation | Q47979466 | ||
| Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template | Q48190057 | ||
| Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden | Q48217013 | ||
| Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. | Q48229587 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network | Q28280607 | ||
| Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database | Q28280965 | ||
| Evolutionary descent of prion genes from the ZIP family of metal ion transporters | Q28476226 | ||
| Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro | Q28584697 | ||
| Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles | Q28589989 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Iron, brain ageing and neurodegenerative disorders | Q29615656 | ||
| Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up | Q30457611 | ||
| Imaging iron stores in the brain using magnetic resonance imaging | Q30983609 | ||
| Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS. | Q31011527 | ||
| Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein | Q31120123 | ||
| Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. | Q33229900 | ||
| Mechanisms of copper ion mediated Huntington's disease progression | Q33280572 | ||
| Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease | Q33292417 | ||
| Copper (II) modulates in vitro aggregation of a tau peptide | Q33301784 | ||
| Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia | Q33322579 | ||
| Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells | Q33323232 | ||
| Abnormal brain iron homeostasis in human and animal prion disorders | Q33417668 | ||
| Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport | Q33476856 | ||
| Prion protein regulates iron transport by functioning as a ferrireductase | Q33744807 | ||
| Targeting chelatable iron as a therapeutic modality in Parkinson's disease | Q33768106 | ||
| Alpha-synuclein is a cellular ferrireductase | Q33798034 | ||
| Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders | Q33847248 | ||
| Existing and emerging mechanisms for transport of iron and manganese to the brain | Q33897532 | ||
| Design of iron chelators with therapeutic application | Q34258805 | ||
| Chelating agents for neurodegenerative diseases | Q34267042 | ||
| A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains | Q34300345 | ||
| Therapeutic advances in neurodegeneration with brain iron accumulation. | Q34306648 | ||
| Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. | Q34310530 | ||
| Prevalence of iron deficiency in children with Down syndrome | Q34336451 | ||
| Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis | Q34407914 | ||
| Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation | Q34575740 | ||
| Selective iron chelation in Friedreich ataxia: biologic and clinical implications | Q48231374 | ||
| Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication | Q48298527 | ||
| Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE | Q48328637 | ||
| Ferroportin in the postnatal rat brain: implications for axonal transport and neuronal export of iron | Q48371767 | ||
| Dietary and genetically-induced oxidative stress alter tau phosphorylation: influence of folate and apolipoprotein E deficiency | Q48444267 | ||
| Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects | Q48548870 | ||
| Iron deposits in multiple sclerosis and Alzheimer's disease brains | Q48682014 | ||
| Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. | Q48686425 | ||
| Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress | Q48861931 | ||
| Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. | Q48898990 | ||
| Expression of divalent metal transporter 1 in primary hippocampal neurons: reconsidering its role in non-transferrin-bound iron influx. | Q50507011 | ||
| Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. | Q52243684 | ||
| β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. | Q52604748 | ||
| The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. | Q53242907 | ||
| Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. | Q53265841 | ||
| Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. | Q53317622 | ||
| Iron(II) binding to amyloid-β, the Alzheimer's peptide. | Q53321099 | ||
| Copper- and iron-induced differential fibril formation in α-synuclein: TEM study | Q57459956 | ||
| An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta | Q57962773 | ||
| Interaction of α-Synuclein with Divalent Metal Ions Reveals Key Differences: A Link between Structure, Binding Specificity and Fibrillation Enhancement | Q58484316 | ||
| Sequestration of iron by Lewy bodies in Parkinson's disease | Q64771847 | ||
| Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions | Q71894700 | ||
| Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus | Q72502492 | ||
| Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population | Q79164457 | ||
| The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 | ||
| Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures | Q80089281 | ||
| Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention | Q82968961 | ||
| Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity | Q95721056 | ||
| The role of metallobiology and amyloid-β peptides in Alzheimer's disease | Q37961769 | ||
| The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis | Q38018281 | ||
| Prion propagation, toxicity and degradation | Q38021894 | ||
| Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators | Q38078728 | ||
| Iron metabolism in the CNS: implications for neurodegenerative diseases | Q38118885 | ||
| Prion protein facilitates uptake of zinc into neuronal cells | Q39258090 | ||
| Overexpression of human wild-type amyloid-β protein precursor decreases the iron content and increases the oxidative stress of neuroblastoma SH-SY5Y cells | Q39373390 | ||
| Thalassaemia | Q39708856 | ||
| Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. | Q39754066 | ||
| Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease | Q39774883 | ||
| MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study | Q39979236 | ||
| Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial | Q40064054 | ||
| Huntingtin inclusion bodies are iron-dependent centers of oxidative events. | Q40206245 | ||
| ??? | Q64767196 | ||
| Immunohistochemical localization of TRPC6 in the rat substantia nigra | Q34667843 | ||
| Metalloproteins and metal sensing | Q34997092 | ||
| Iron accumulates in Huntington's disease neurons: protection by deferoxamine | Q35023030 | ||
| Anemia in children with down syndrome | Q35215325 | ||
| Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. | Q35322005 | ||
| Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics | Q35571525 | ||
| MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping | Q35663179 | ||
| Oxygen radicals as key mediators in neurological disease: fact or fiction? | Q35753839 | ||
| Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. | Q35754533 | ||
| Carboxyl-terminal fragments of beta-amyloid precursor protein bind to microtubules and the associated protein tau | Q35763640 | ||
| Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains | Q35777814 | ||
| Physiologic implications of metal-ion transport by ZIP14 and ZIP8 | Q36138755 | ||
| Prions and their partners in crime | Q36628157 | ||
| HFE mutations and Alzheimer's disease | Q36660095 | ||
| Altered regulation of iron transport and storage in Parkinson's disease. | Q36797088 | ||
| Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet | Q36819515 | ||
| Iron: the Redox-active center of oxidative stress in Alzheimer disease | Q36824768 | ||
| Alterations in brain transition metals in Huntington disease: an evolving and intricate story | Q36838442 | ||
| A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease | Q36875682 | ||
| Brain iron metabolism: neurobiology and neurochemistry. | Q36942795 | ||
| High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron. | Q36948901 | ||
| Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease | Q36985218 | ||
| Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators | Q37019628 | ||
| Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis | Q37087487 | ||
| A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. | Q37258755 | ||
| Iron, the substantia nigra and related neurological disorders | Q37263474 | ||
| A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism | Q37285877 | ||
| MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice | Q37295234 | ||
| Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis | Q37455882 | ||
| Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics | Q37742819 | ||
| Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: a short review | Q37790095 | ||
| Genetic Analysis of Pathways to Parkinson Disease | Q37801078 | ||
| Reorganizing metals: the use of chelating compounds as potential therapies for metal-related neurodegenerative disease | Q37824339 | ||
| HFE gene variants affect iron in the brain | Q37846398 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 81 | |
| P577 | publication date | 2014-04-21 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders | |
| P478 | volume | 5 |
| Q38967236 | Bioavailable Trace Metals in Neurological Diseases |
| Q46426248 | Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. |
| Q36033901 | Contributions to magnetic susceptibility of brain tissue |
| Q92363257 | High Dietary Iron Disrupts Iron Homeostasis and Induces Amyloid-β and Phospho-τ Expression in the Hippocampus of Adult Wild-Type and APP/PS1 Transgenic Mice |
| Q26775146 | Iron Homeostasis in Health and Disease |
| Q33695111 | Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine Metabolism and Cellular Prion Protein in a Region-Specific Manner |
| Q33776138 | Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease |
| Q41829749 | Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. |
| Q31038817 | Role of iron in neurodegenerative diseases |
| Q43160189 | The importance of iron in pathophysiologic conditions |
| Q38675074 | The prion-ZIP connection: From cousins to partners in iron uptake |
| Q35260802 | The role of iron in prion disease and other neurodegenerative diseases |
| Q48220225 | Understanding metal homeostasis in primary cultured neurons. Studies using single neuron subcellular and quantitative metallomics |
| Q26382049 | Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy |
| Q51759208 | Unraveling the Burden of Iron in Neurodegeneration: Intersections with Amyloid Beta Peptide Pathology. |
| Q30835947 | Uptake and metabolism of iron oxide nanoparticles in brain cells. |
| Q38892026 | α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. |
| Q34612398 | β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin |
Search more.